Skip to main content

BIO-TECHNE Corp stock price and financials

  • TECH · Nasdaq
  • Biotechnology
  • Life Sciences Tools & Services
  • S&P 500
$72.80−0.05%Close 13 Nov 2026
EV / EBITDA
33.68
Beta · 1 year
0.64
Return · 1 year
+18.6%
52-week range$43.20 — $72.88

Share price close 16 Nov 2026

+0.4%1 monthHigh $72.84Low $72.49
$72.4$72.5$72.6$72.7$72.8$72.9Q1 FY2027 report filed 6 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+68.2%6 monthsHigh $72.84Low $44.43
$40$50$60$70$80Q4 FY2026 report filed 24 Aug 2026Q1 FY2027 report filed 6 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+23.8%year to dateHigh $72.84Low $43.30
$40$50$60$70$80Q2 FY2026 report filed 4 Feb 2026Q3 FY2026 report filed 6 May 2026Q4 FY2026 report filed 24 Aug 2026Q1 FY2027 report filed 6 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+22.6%1 yearHigh $72.84Low $43.30
$40$50$60$70$80Q2 FY2026 report filed 4 Feb 2026Q3 FY2026 report filed 6 May 2026Q4 FY2026 report filed 24 Aug 2026Q1 FY2027 report filed 6 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+19.6%3 yearsHigh $84.15Low $43.30
$40$60$80$100Q2 FY2024 report filed 7 Feb 2024Q3 FY2024 report filed 6 May 2024Q4 FY2024 report filed 22 Aug 2024Q1 FY2025 report filed 5 Nov 2024Q2 FY2025 report filed 6 Feb 2025Q3 FY2025 report filed 8 May 2025Q4 FY2025 report filed 22 Aug 2025Q1 FY2026 report filed 5 Nov 2025Q2 FY2026 report filed 4 Feb 2026Q3 FY2026 report filed 6 May 2026Q4 FY2026 report filed 24 Aug 2026Q1 FY2027 report filed 6 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+178%10 yearsHigh $134.72Low $24.50
$0$50$100$150Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

BIO-TECHNE Corp reported revenue of $1.22 billion for fiscal year 2026 (the twelve months to 30 Jun 2026), down 0.4% from fiscal 2025. Net income was $182 million and diluted earnings per share $1.16.

In its latest reported quarter, the first quarter of fiscal 2027 (the three months to 30 Sep 2026), revenue was $300 million, up 4.6% from a year earlier.

Figures from BIO-TECHNE Corp's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 6 Nov 2026.

Revenue FY2026
$1.22B−0.4%
Net income
$181.8M+148%
Diluted EPS
$1.16+152%
Gross margin
65.8%+1.0 pts
Free cash flow
$263.2M+2.6%
Net debt
$24.38M−91.4%

Fiscal 2026 against fiscal 2025; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2017–2026

  • Revenue
  • Net income
$0$250M$500M$750M$1B$1.25BRevenue, FY17: $563MNet income, FY17: $76.09MFY17Revenue, FY18: $642.99MNet income, FY18: $126.15MFY18Revenue, FY19: $714.01MNet income, FY19: $96.07MFY19Revenue, FY20: $738.69MNet income, FY20: $229.3MFY20Revenue, FY21: $931.03MNet income, FY21: $140.41MFY21Revenue, FY22: $1.11BNet income, FY22: $272.05MFY22Revenue, FY23: $1.14BNet income, FY23: $285.26MFY23Revenue, FY24: $1.16BNet income, FY24: $168.07MFY24Revenue, FY25: $1.22BNet income, FY25: $73.36MFY25Revenue, FY26: $1.22BNet income, FY26: $181.84MFY26

Latest quarter · Q1 FY2027 to 30 Sep 2026, filed 6 Nov 2026 · Full results →

Revenue
$299.7M+4.6% on a year
Gross margin
65.6%0.0 pts on a year
Operating income
$36.60M−23.2% on a year
Net income
$28.29M−25.9% on a year
Diluted EPS
$0.18−25.0% on a year
Free cash flow
$67.20M+202% on a year

Comparable companies All of Health Care →

BIO-TECHNE Corp beside the other S&P 500 members in Life Sciences Tools & Services, by market value.

BIO-TECHNE Corp and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Bio-TechneTECH—−0.1%+18.6%———
Danaher CorporationDHR$163.0B+0.4%+6.2%+5.5%16.9%37.6
Agilent TechnologiesA$48.72B+0.5%+14.8%+8.6%19.5%33.8
IQVIAIQV$43.52B−2.2%+20.0%+8.8%8.1%31.2
IlluminaILMN$30.43B−4.2%+65.3%+5.8%19.7%34.0
Charles River LaboratoriesCRL$16.06B−0.8%+97.1%−1.2%1.0%399.6
Mettler ToledoMTD—+0.5%+20.1%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2017–2026

  • Gross
  • Operating
  • Net
0%25%50%75%65.8%20.7%15.0%FY17FY20FY23FY26

BIO-TECHNE Corp revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

BIO-TECHNE Corp revenue by segment, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025FY 2026
Protein Sciences$832.3M$845.7M+1.6%$830.9M−1.8%$870.2M+4.7%$874.6M+0.5%
Diagnostics and Spatial Biology$274.8M$292.6M+6.5%$326.4M+11.5%$346.3M+6.1%$336.4M−2.9%
Not allocated to a line————$4.05M
Total revenue$1.11B$1.14B$1.16B$1.22B$1.22B

By product

BIO-TECHNE Corp revenue by product, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025FY 2026
Consumables$890.9M$917.7M+3.0%$928.2M+1.1%$972.3M+4.8%$985.1M+1.3%
Instruments$120.8M$112.1M−7.2%$108.3M−3.4%$112.1M+3.5%$110.6M−1.3%
Services$71.99M$85.78M+19.2%$99.27M+15.7%$111.6M+12.4%$94.30M−15.5%
Royalty$21.98M$21.10M−4.0%$23.34M+10.6%$23.69M+1.5%$24.99M+5.5%
Total revenue$1.11B$1.14B$1.16B$1.22B$1.22B

By region

BIO-TECHNE Corp revenue by region, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025FY 2026
United States$614.1M$642.5M+4.6%$657.7M+2.4%$683.2M+3.9%$635.4M−7.0%
EMEA, excluding United Kingdom$219.1M$220.2M+0.5%$241.4M+9.6%$266.3M+10.3%$294.2M+10.5%
China$112.4M$113.9M+1.3%$99.47M−12.6%$100.5M+1.0%$104.1M+3.6%
APAC, excluding Greater China$76.14M$73.19M−3.9%$73.90M+1.0%$77.26M+4.5%$85.81M+11.1%
United Kingdom$48.64M$49.46M+1.7%$50.01M+1.1%$54.83M+9.6%$56.28M+2.7%
Rest of World$35.22M$37.49M+6.4%$36.50M−2.7%$37.55M+2.9%$39.28M+4.6%
Total revenue$1.11B$1.14B$1.16B$1.22B$1.22B

Financial statements

Fiscal years, the latest ending 30 Jun 2026. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

BIO-TECHNE Corp income statement, annual
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Revenue$563.0M$643.0M$714.0M$738.7M$931.0M$1.11B$1.14B$1.16B$1.22B$1.22B
Revenue growth+12.8%+14.2%+11.0%+3.5%+26.0%+18.7%+2.8%+2.0%+5.2%−0.4%
Gross profit$374.5M$432.1M$473.5M$483.2M$632.9M$756.5M$769.8M$769.7M$790.3M$799.1M
Operating income$120.6M$136.2M$146.7M$157.4M$237.3M$296.6M$298.9M$206.7M$102.3M$251.9M
Net income$76.09M$126.2M$96.07M$229.3M$140.4M$272.1M$285.3M$168.1M$73.36M$181.8M
Diluted EPS$0.51$0.83$0.62$1.45$0.87$1.66$1.76$1.05$0.46$1.16
Gross margin66.5%67.2%66.3%65.4%68.0%68.4%67.7%66.4%64.8%65.8%
Operating margin21.4%21.2%20.5%21.3%25.5%26.8%26.3%17.8%8.4%20.7%
Net margin13.5%19.6%13.5%31.0%15.1%24.6%25.1%14.5%6.0%15.0%

Cash flow

BIO-TECHNE Corp cash flow, annual
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Operating cash flow$143.7M$170.4M$181.6M$205.2M$352.2M$325.3M$254.4M$299.0M$287.6M$292.1M
Capital expenditure$15.18M$20.93M$25.41M$51.74M$44.30M$44.91M$38.24M$62.88M$31.01M$28.85M
Free cash flow$128.5M$149.4M$156.2M$153.5M$307.9M$280.4M$216.1M$236.1M$256.6M$263.2M

Balance sheet and shares

BIO-TECHNE Corp balance sheet and shares, annual
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Cash and equivalents$91.61M$122.0M$100.9M$146.6M$199.1M$172.6M$180.6M$151.8M$162.2M$264.7M
Total debt$343.8M$339.0M$505.2M$433.5M$420.6M$326.0M$455.0M$419.5M$444.1M$289.1M
Shareholders' equity$949.6M$1.08B$1.17B$1.38B$1.56B$1.70B$1.97B$2.07B$1.92B$2.11B
Diluted shares150M152M156M158M162M164M162M161M160M157M
Dividends per share$0.32$0.32$0.32$0.32$0.32$0.80$0.32$0.32$0.32$0.32

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

BIO-TECHNE Corp quarterly financial figures
PeriodQ2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027
Revenue$297.0M$316.2M$317.0M$286.6M$295.9M$311.4M$321.2M$299.7M
Revenue, year on year+9.0%+4.2%+3.5%−1.0%−0.4%−1.5%+1.3%+4.6%
Gross margin65.3%67.9%62.7%65.6%64.6%66.9%65.8%65.6%
Operating income$47.42M$38.71M−$23.86M$47.66M$54.46M$75.50M$74.28M$36.60M
Net income$34.89M$22.59M−$17.70M$38.18M$38.00M$51.04M$54.64M$28.29M
Diluted EPS$0.22$0.14−$0.11$0.24$0.24$0.32$0.35$0.18
Free cash flow$77.53M$31.00M$93.31M$22.22M$76.49M$77.58M$86.94M$67.20M

Operating KPIs

The operating figures BIO-TECHNE Corp reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

BIO-TECHNE Corp operating KPIs
KPILatestPeriodChange on a yearRecent periods
Product and Services revenue$285.2Mquarter to 30 Sep 2026up 1.5%
Consumables revenue$237.3Mquarter to 30 Sep 2026up 2.4%
Instruments revenue$25.5Mquarter to 30 Sep 2026up 16.8%
Services revenue$22.5Mquarter to 30 Sep 2026down 18.3%
Royalty revenue$14.5Mquarter to 30 Sep 2026up 156.7%
Protein Sciences revenue$219.7Mquarter to 30 Sep 2026up 8.7%
Diagnostics and Spatial Biology revenue$80.2Mquarter to 30 Sep 2026up 0.9%
United States revenue$152.7Mquarter to 30 Sep 2026down 1.7%
EMEA, excluding United Kingdom revenue$73.9Mquarter to 30 Sep 2026up 13.5%
China revenue$28.9Mquarter to 30 Sep 2026up 16.6%
APAC, excluding Greater China revenue$22.5Mquarter to 30 Sep 2026up 17.3%
United Kingdom revenue$13.7Mquarter to 30 Sep 2026up 4.0%
Rest of World revenue$8.1Mquarter to 30 Sep 2026down 11.0%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was BIO-TECHNE Corp's revenue in fiscal 2026?

$1.22 billion for fiscal year 2026 (the twelve months to 30 Jun 2026), as reported in its annual report.

What was BIO-TECHNE Corp's net income in fiscal 2026?

$182 million for fiscal year 2026 (the twelve months to 30 Jun 2026).

What were BIO-TECHNE Corp's diluted earnings per share in fiscal 2026?

$1.16 for fiscal year 2026 (the twelve months to 30 Jun 2026).

What is BIO-TECHNE Corp's gross margin?

65.8% for fiscal year 2026 (the twelve months to 30 Jun 2026): gross profit divided by revenue.

What is BIO-TECHNE Corp's operating margin?

20.7% for fiscal year 2026 (the twelve months to 30 Jun 2026): operating income divided by revenue.

How much free cash flow did BIO-TECHNE Corp generate in fiscal 2026?

$263 million for fiscal year 2026 (the twelve months to 30 Jun 2026): operating cash flow less capital expenditure.

Where does BIO-TECHNE Corp's revenue come from?

In fiscal 2026, by segment: Protein Sciences $874.6M (72%), Diagnostics and Spatial Biology $336.4M (28%), out of $1.22B in all, as stated in its annual report.

In the terminal

Twenty years of BIO-TECHNE Corp's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans